溶血磷脂酸调控骨改建作用的研究进展

doi:10.13591/j.cnki.kqyx.2024.09.010

Abstract

Abstract:

Lysophosphatidic acid (LPA), a simple bioactive lysophospholipid widely dispersed in human body, has been reported to regulate the proliferation, chemotaxis and differentiation of multiple cells and further participate in various developmental and pathophysiological processes through at least six specific G protein-coupled receptors (GPCRs), LPA₁-LPA₆. Recently, the possibility of targeting LPA or LPA receptors in bone remodeling has been heatedly discussed. On the one hand, LPA modulate the activities of bone-related cells directly. On the other hand, LPA might be the potential regulator that links the nervous-vascular-immune-skeletal systems, which could provide a good microenvironment for bone remodeling and further promote bone regeneration. Thus, this review summarizes recent studies on the effects and application prospect of LPA on bone remodeling.

Key words: lysophosphatidic acid, bone remodeling, G-proteincoupledreceptor

CLC Number:

R344.3

ZHANG Qin, XIANG Lin, GONG Ping. Advances in lysophosphatidic acid for bone remodeling[J]. Stomatology, 2024, 44(9): 699-704.

References 85

[1]	Olsen BR, Reginato AM, Wang WF. Bone development[J]. Annu Rev Cell Dev Biol, 2000, 16: 191-220. pmid: 11031235
[2]	Nishimura I. Genetic networks in osseointegration[J]. J Dent Res, 2013, 92(12 Suppl): 109S-118S.
[3]	Rodríguez-Gómez I, Mañas A, Losa-Reyna J, et al. Compositional influence of movement behaviors on bone health during aging[J]. Med Sci Sports Exerc, 2019, 51(8): 1736-1744.
[4]	Lummis NC, Sánchez-Pavón P, Kennedy G, et al. LPA_1/3overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction[J]. Sci Adv, 2019, 5(10): eaax2011.
[5]	Yang LP, Kraemer M, Fang XF, et al. LPA receptor 4 deficiency attenuates experimental atherosclerosis[J]. J Lipid Res, 2019, 60(5): 972-980. doi: 10.1194/jlr.M091066 pmid: 30796085
[6]	Zhao PF, Wu S, Li Y, et al. LPA receptor1 antagonists as anticancer agents suppress human lung tumours[J]. Eur J Pharmacol, 2020, 868: 172886.
[7]	Chen WM, Chiang JC, Lin YC, et al. Lysophosphatidic acid receptor LPA₃ prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome[J]. Aging Cell, 2020, 19(1): e13064.
[8]	Wu XN, Ma YY, Su NC, et al. Lysophosphatidic acid: Its role in bone cell biology and potential for use in bone regeneration[J]. Prostaglandins Other Lipid Mediat, 2019, 143: 106335.
[9]	Alioli C, Demesmay L, Peyruchaud O, et al. Autotaxin/lysophosphatidic acid axis: From bone biology to bone disorders[J]. Int J MolSci, 2022, 23(7): 3427.
[10]	Cerutis DR, Weston MD, Miyamoto T. Entering, linked with the Sphinx: Lysophosphatidic acids everywhere, all at once, in the oral system and cancer[J]. Int J Mol Sci, 2023, 24(12): 10278.
[11]	Blackburn J, Mansell JP. The emerging role of lysophosphatidic acid (LPA) in skeletal biology[J]. Bone, 2012, 50(3): 756-762. doi: 10.1016/j.bone.2011.12.002 pmid: 22193551
[12]	吴湘楠, 马媛媛, 浩志超, 等. 溶血磷脂酸对骨组织细胞生物学调控功能的研究进展[J]. 华西口腔医学杂志, 2020, 38(3): 328-333.
[13]	Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets[J]. Biochem J, 1993, 291 (Pt 3):677-680.
[14]	Panupinthu N, Rogers JT, Zhao L, et al. P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: A signaling axis promoting osteogenesis[J]. J Cell Biol, 2008, 181(5): 859-871. doi: 10.1083/jcb.200708037 pmid: 18519738
[15]	Panupinthu N, Zhao L, Possmayer F, et al. P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid[J]. J Biol Chem, 2007, 282(5): 3403-3412. doi: 10.1074/jbc.M605620200 pmid: 17135244
[16]	Karagiosis SA, Karin NJ. Lysophosphatidic acid induces osteocyte dendrite outgrowth[J]. Biochem Biophys Res Commun, 2007, 357(1): 194-199.
[17]	Yanagida K, Ishii S. Non-Edg family LPA receptors: The cutting edge of LPA research[J]. J Biochem, 2011, 150(3): 223-232. doi: 10.1093/jb/mvr087 pmid: 21746769
[18]	Choi JW, Herr DR, Noguchi K, et al. LPA receptors: Subtypes and biological actions[J]. Annu Rev Pharmacol Toxicol, 2010, 50: 157-186. doi: 10.1146/annurev.pharmtox.010909.105753 pmid: 20055701
[19]	Cho KH, JeongBY, Park CG, et al. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion[J]. Arch Pharm Res, 2019, 42(6): 519-530. doi: 10.1007/s12272-019-01149-6 pmid: 31004257
[20]	Wu XN, Ma YY, Chen HL, et al. Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through activation of the LPA₁ receptor and PKCθ signaling pathway[J]. Int Immunopharmacol, 2019, 74: 105664.
[21]	Lorthongpanich C, Thumanu K, Tangkiettrakul K, et al. YAP as a key regulator of adipo-osteogenic differentiation in human MSCs[J]. Stem Cell Res Ther, 2019, 10(1): 402.
[22]	Masiello LM, Fotos JS, Galileo DS, et al. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells[J]. Bone, 2006, 39(1): 72-82. pmid: 16487757
[23]	Mansell JP, Nowghani M, Pabbruwe M, et al. Lysophosphatidic acid and calcitriol co-operate to promote human osteoblastogenesis: Requirement of albumin-bound LPA[J]. Prostaglandins Other Lipid Mediat, 2011, 95(1/2/3/4): 45-52.
[24]	Liu YB, Kharode Y, Bodine PVN, et al. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4[J]. J Cell Biochem, 2010, 109(4): 794-800.
[25]	Grey A, Banovic T, Naot D, et al. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases[J]. Endocrinology, 2001, 142(3): 1098-1106. pmid: 11181524
[26]	Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass[J]. Bone, 2011, 49(3): 395-403. doi: 10.1016/j.bone.2011.04.018 pmid: 21569876
[27]	Alioli CA, Demesmay L, Laurencin-Dalacieux S, et al. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification[J]. Biochim Biophys Acta BBA Mol Cell Biol Lipds, 2020, 1865(8): 158715.
[28]	Karagiosis SA, Chrisler WB, Bollinger N, et al. Lysophosphatidic acid-induced ERK activation and chemotaxis in MC3T3-E1 preosteoblasts are independent of EGF receptor transactivation[J]. J Cell Physiol, 2009, 219(3): 716-723. doi: 10.1002/jcp.21720 pmid: 19189345
[29]	Wang XY, Fan XS, Cai L, et al. Lysophosphatidic acid rescues bone mesenchymal stem cells from hydrogen peroxide-induced apoptosis[J]. Apoptosis, 2015, 20(3): 273-284.
[30]	Chen JH, Baydoun AR, Xu RX, et al. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis[J]. Stem Cells, 2008, 26(1): 135-145. doi: 10.1634/stemcells.2007-0098 pmid: 17932426
[31]	Yao SC, Zhang YN, Wang XY, et al. Pigment epithelium-derived factor (PEDF) protects osteoblastic cell line from glucocorticoid-induced apoptosis via PEDF-R[J]. Int J Mol Sci, 2016, 17(5): 730.
[32]	Wang JS, Kamath T, Mazur CM, et al. Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin[J]. Nat Commun, 2021, 12(1): 6271.
[33]	Waters KM, Jacobs JM, Gritsenko MA, et al. Regulation of gene expression and subcellular protein distribution in MLO-Y4 osteocytic cells by lysophosphatidic acid: Relevance to dendrite outgrowth[J]. Bone, 2011, 48(6): 1328-1335. doi: 10.1016/j.bone.2011.02.020 pmid: 21356339
[34]	David M, Machuca-Gayet I, Kikuta J, et al. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity[J]. J Biol Chem, 2014, 289(10): 6551-6564. doi: 10.1074/jbc.M113.533232 pmid: 24429286
[35]	Kim TY, Kim A, Aryal YP, et al. Functional modulation of lysophosphatidic acid type 2 G-protein coupled receptor facilitates alveolar bone formation[J]. J Cell Physiol, 2024, 239(1): 112-123.
[36]	Kostadinova L, Shive CL, Anthony DD. Elevated autotaxin and LPA levels during chronic viral hepatitis and hepatocellular carcinoma associate with systemic immune activation[J]. Cancers, 2019, 11(12): 1867.
[37]	Gaire BP, Sapkota A, Song MR, et al. Lysophosphatidic acid receptor 1 (LPA₁) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia[J]. J Neuroinflammation, 2019, 16(1): 170.
[38]	Peng J, Liu MM, Liu HH, et al. Lipoprotein (a)-mediated vascular calcification: Population-based and in vitro studies[J]. Metabolism, 2022, 127: 154960.
[39]	Eghbali-Fatourechi GZ, Lamsam J, Fraser D, et al. Circulating osteoblast-lineage cells in humans[J]. N Engl J Med, 2005, 352(19): 1959-1966.
[40]	Offermanns S, Mancino V, Revel JP, et al. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency[J]. Science, 1997, 275(5299): 533-536. doi: 10.1126/science.275.5299.533 pmid: 8999798
[41]	Kamijo H, Matsumura Y, Thumkeo D, et al. Impaired vascular remodeling in the yolk sac of embryos deficient in ROCK-Ⅰ and ROCK-Ⅱ[J]. Genes Cells, 2011, 16(10): 1012-1021.
[42]	Yasuda D, Kobayashi D, Akahoshi N, et al. Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4[J]. J Clin Invest, 2019, 129(10): 4332-4349. doi: 10.1172/JCI121955 pmid: 31335323
[43]	Zhao Y, Hasse S, Zhao CQ, et al. Targeting the autotaxin-Lysophosphatidic acid receptor axis in cardiovascular diseases[J]. Biochem Pharmacol, 2019, 164: 74-81.
[44]	Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis[J]. Circ Res, 2016, 118(4): 620-636. doi: 10.1161/CIRCRESAHA.115.306301 pmid: 26892962
[45]	Lin CI, Chen CN, Huang MT, et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms[J]. Cell Signal, 2008, 20(10): 1804-1814.
[46]	Gustin C, van Steenbrugge M, Raes M. Circulating osteoblast-lineage cells in humans[J]. N Engl J Med, 2005, 352(19): 1959-1966.
[47]	Nich C, Takakubo Y, Pajarinen J, et al. Macrophages-Key cells in the response to wear debris from joint replacements[J]. J Biomed Mater Res A, 2013, 101(10): 3033-3045. doi: 10.1002/jbm.a.34599 pmid: 23568608
[48]	Vi L, Baht GS, Whetstone H, et al. Macrophages promote osteoblastic differentiation in-vivo: Implications in fracture repair and bone homeostasis[J]. J Bone Miner Res, 2015, 30(6): 1090-1102.
[49]	Chang MK, Raggatt LJ, Alexander KA, et al. Ostealtissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo[J]. J Immunol, 2008, 181(2): 1232-1244. doi: 10.4049/jimmunol.181.2.1232 pmid: 18606677
[50]	Bastian O, Pillay J, Alblas J, et al. Systemic inflammation and fracture healing[J]. J Leukoc Biol, 2011, 89(5): 669-673.
[51]	Wu AC, Raggatt LJ, Alexander KA, et al. Unraveling macrophage contributions to bone repair[J]. Bonekey Rep, 2013, 2: 373.
[52]	Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8(12): 958-969. doi: 10.1038/nri2448 pmid: 19029990
[53]	Kozian DH, von Haeften E, Joho S, et al. Modulation of hexadecyl-LPA-mediated activation of mast cells and microglia by a chemical probe for LPA5[J]. Chembiochem, 2016, 17(9): 861-865. doi: 10.1002/cbic.201500559 pmid: 26812365
[54]	Bai ZB, Cai LJ, Umemoto E, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venulesis regulated by the autotaxin/lysophosphatidic acid axis[J]. J Immunol, 2013, 190(5): 2036-2048.
[55]	Takeda A, Kobayashi D, Aoi K, et al. Fibroblastic reticular cell-derived lysophosphatidic acid regulates confined intranodal T-cell motility[J]. eLife, 2016, 5: e10561.
[56]	Ray R, Rai V. Lysophosphatidic acid converts monocytes into macrophages in both mice and humans[J]. Blood, 2017, 129(9): 1177-1183. doi: 10.1182/blood-2016-10-743757 pmid: 28069607
[57]	Chen LM, Zhang J, Deng X, et al. Lysophosphatidic acid directly induces macrophage-derived foam cell formation by blocking the expression of SRBI[J]. Biochem Biophys Res Commun, 2017, 491(3): 587-594.
[58]	Rizza C, Leitinger N, Yue J, et al. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction[J]. Lab Invest, 1999, 79(10): 1227-1235. pmid: 10532586
[59]	Hashimura S, Kido J, Matsuda R, et al. A low level of lysophosphatidic acid in human gingival crevicular fluid from patients with periodontitis due to high soluble lysophospholipase activity: Its potential protective role on alveolar bone loss by periodontitis[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(7): 158698.
[60]	Lerner UH. Neuropeptidergic regulation of bone resorption and bone formation[J]. J Musculoskelet Neuronal Interact, 2002, 2(5): 440-447. pmid: 15758412
[61]	García-Castellano JM, Díaz-Herrera P, Morcuende JA. Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions[J]. Iowa Orthop J, 2000, 20: 49-58. pmid: 10934625
[62]	Beeve AT, Brazill JM, Scheller EL. Peripheral neuropathy as a component of skeletal disease in diabetes[J]. Curr Osteoporos Rep, 2019, 17(5): 256-269. doi: 10.1007/s11914-019-00528-8 pmid: 31392667
[63]	Inoue M, Rashid MH, Fujita R, et al. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling[J]. Nat Med, 2004, 10(7): 712-718. doi: 10.1038/nm1060 pmid: 15195086
[64]	Ahn DK, Lee SY, Han SR, et al. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats[J]. Pain, 2009, 146(1/2): 114-120.
[65]	Nieto-Posadas A, Picazo-Juárez G, Llorente I, et al. Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site[J]. Nat Chem Biol, 2011, 8(1): 78-85. doi: 10.1038/nchembio.712 pmid: 22101604
[66]	Yu XJ, Lv LL, Zhang J, et al. Expression of neuropeptides and bone remodeling-related factors during periodontal tissue regeneration in denervated rats[J]. J Mol Histol, 2015, 46(2): 195-203. doi: 10.1007/s10735-015-9611-x pmid: 25663522
[67]	Wang TL, GuoYJ, Yuan Y, et al. Deficiency of α Calcitonin-gene-related peptide impairs peri-implant angiogenesis and osseointegration via suppressive vasodilative activity[J]. Biochem Biophys Res Commun, 2018, 498(1): 139-145.
[68]	Xiang L, Ma L, Wei N, et al. Effect of lentiviral vector overexpression α-calcitonin gene-related peptide on titanium implant osseointegration in α-CGRP-deficient mice[J]. Bone, 2017, 94: 135-140. doi: S8756-3282(15)00320-8 pmid: 26265538
[69]	Mikami R, Mizutani K, Aoki A, et al. Low-level ultrahigh-frequency and ultrashort-pulse blue laser irradiation enhances osteoblast extracellular calcification by upregulating proliferation and differentiation via transient receptor potential vanilloid 1[J]. Lasers SurgMed, 2018, 50(4): 340-352.
[70]	Xiao F, Zhou Y, Liu YF, et al. Inhibitory effect of Sirtuin6 (SIRT6) on osteogenic differentiation of bone marrow mesenchymal stem cells[J]. Med Sci Monit, 2019, 25: 8412-8421.
[71]	Takahashi N, Matsuda Y, Sato K, et al. Neuronal TRPV1 activation regulates alveolar bone resorption by suppressing osteoclastogenesis via CGRP[J]. Sci Rep, 2016, 6: 29294. doi: 10.1038/srep29294 pmid: 27388773
[72]	Borrelli MJ, Youssef A, Boffa MB, et al. New frontiers in lp(a)-targeted therapies[J]. Trends Pharmacol Sci, 2019, 40(3): 212-225. doi: S0165-6147(19)30015-X pmid: 30732864
[73]	Julius U, Tselmin S, Schatz U, et al. Lipoprotein(a)-an interdisciplinary challenge[J]. Clin Res Cardiol Suppl, 2019, 14(Suppl 1): 20-27. doi: 10.1007/s11789-019-00098-0 pmid: 30838556
[74]	Soond SM, JrZamyatnin AA. Targeting G protein-coupled receptors in cancer therapy[J]. Adv Cancer Res, 2020, 145: 49-97. doi: S0065-230X(19)30062-4 pmid: 32089165
[75]	Zhou Y, Little PJ, Ta HT, et al. Lysophosphatidic acid and its receptors: Pharmacology and therapeutic potential in atherosclerosis and vascular disease[J]. Pharmacol Ther, 2019, 204: 107404.
[76]	Xing DL, Zuo W, Chen JH, et al. Spatial delivery of triple functional nanoparticles via an extracellular matrix-mimicking coaxial scaffold synergistically enhancing bone regeneration[J]. ACS Appl Mater Interfaces, 2022, 14(33): 37380-37395.
[77]	Baldwin F, Craig TJ, Shiel AI, et al. Polydopamine-lysophosphatidate-functionalisedtitanium: A novel hybrid surface finish for bone regenerative applications[J]. Molecules, 2020, 25(7): 1583.
[78]	Mansell JP, Barbour M, Moore C, et al. The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces[J]. Biomaterials, 2010, 31(2): 199-206. doi: 10.1016/j.biomaterials.2009.09.035 pmid: 19796809
[79]	Bosetti M, Borrone A, Leigheb M, et al. ^*Injectable graft substitute active on bone tissue regeneration[J]. Tissue Eng Part A, 2017, 23(23/24): 1413-1422.
[80]	Might KR, Martinez SA, Karin N, et al. The effect of lysophosphatidic acid using a hydrogel or collagen sponge carrier on bone healing in dogs[J]. Vet Comp Orthop Traumatol, 2016, 29(4): 306-313. doi: 10.3415/VCOT-15-08-0137 pmid: 27432270
[81]	Yu ZL, Jiao BF, Li ZB. Lysophosphatidic acid analogue rather than lysophosphatidic acid promoted the bone formation in vivo[J]. Biomed Res Int, 2018, 2018: 7537630.
[82]	Minami K, Ueda N, Maeda H, et al. Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA₅ in melanoma cells treated with anticancer drugs[J]. Biochem Biophys Res Commun, 2019, 517(2): 359-363.
[83]	Lei L, Su J, Chen JC, et al. The role of lysophosphatidic acid in the physiology and pathology of the skin[J]. Life Sci, 2019, 220: 194-200. doi: S0024-3205(18)30833-6 pmid: 30584899
[84]	Kaffe E, Magkrioti C, Aidinis V. Deregulated lysophosphatidic acid metabolism and signaling in liver cancer[J]. Cancers, 2019, 11(11): 1626.
[85]	Hussain Z, Iqbal J, Liu HC, et al. Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population[J]. Int J Biol Macromol, 2023, 233: 123586.

Advances in lysophosphatidic acid for bone remodeling

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 85

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	JIANG Zhen, HAN Xue, JIANG Beizhan. Research progress of the regulatory mechanisms of dental follicle in bone remodeling during tooth eruption [J]. Stomatology, 2023, 43(8): 752-756.
[2]	LIN Xiangxiang, YU Fei, SONG Yiwei, WANG Wan, GONG Guoliang, LIN Xinping. Progress of research on influencing factors of alveolar bone remodeling at lip and palate side during maxillary incisor retraction [J]. Stomatology, 2023, 43(11): 1053-1056.
[3]	GONG Xue, QIAN Wenhao, SU Jiansheng. Effects of zoledronate on bone remodeling of maxillofacial and peripheral bones after trauma in rats [J]. Stomatology, 2022, 42(7): 587-592.
[4]	. Mandibular ramus osteotomy-induced changes of oxygen level and alveolar bone remodeling: A rat model [J]. , 2020, 40(10): 869-873.
[5]	Rui-Lin ZHANG. Observation of RANKL/OPG temporal expression and apoptosis of periodontal tissue during alveolar bone remodeling induced by orthodontic force [J]. , 2019, 39(6): 488-493.
[6]	. Effect of different platform-switched widths on peri-implant bone remodeling [J]. , 2018, 38(4): 329-332.
[7]	Ying-Chen Ji. Surgery-first approach in orthgnathic surgery and postoperative accelerated tooth movement phenomenon : A systematic review [J]. , 2017, 37(8): 742-745.
[8]	. The role of FOXO1 in the occurrence and progression of periodontitis. [J]. , 2017, 37(10): 937-941.